Cure Today

Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer

Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...
The New England Journal of Medicine

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 ...
ascopubs.org

Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a ...

Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches Fig 1. Study schema of the GENTLE-Z trial. Patients with previously untreated, CLDN18.2-positive, ...
The New England Journal of Medicine

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and safety of ...
ascopubs.org

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026) This trial adds to the ...